Melinta (Cempra) Priced, Nasdaq: MLNT
Biotech developing potent antibiotics to fight pneumonia and skin infections.
Industry: Health Care
First Day Return: +1.0%
MLNT
Biotech developing potent antibiotics to fight pneumonia and skin infections.
| IPO Data | |
|---|---|
| IPO Date | 02/02/2012 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $50 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Chapel Hill, NC, United States |
| Founded | 2005 |
| Employees at IPO | 15 |
| Website www.cempra.com | |
IPO News for Melinta (Cempra)
Melinta (Cempra) (MLNT) Performance
